5:16 PM
Login form
Entries archive

My site

Main » 2023 » January » 16
  • Baghdad, Iraq - Friday, 13. January 2023
    Views: 64 | Added by: africa-live | Date: 01.16.2023 | Comments (0)

OSAKA, Japan & CAMBRIDGE, Mass. - Friday, 13. January 2023 AETOSWire

– EXKIVITY is the First Category-1 Innovative Drug Approved for Takeda China Following a Phase 2 Global Pivotal Study

– Approval Based on Data from the Phase 1/2 Clinical Trial Demonstrating EXKIVITY’s Clinical Benefit and Durable Responses in EGFR Exon20 Insertion+ NSCLC

– Results Demonstrated a Confirmed Overall Response Rate (ORR) of 28% and Median Duration of Response (DoR) of 15.8 Months per Independent Review Committee (IRC)

(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that EXKIVITY® (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. EXKIVIT ... Read more »

Views: 51 | Added by: africa-live | Date: 01.16.2023 | Comments (0)